BioTech 365

NOVEMBER 9, 2020

AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19 AbCellera-Discovered Antibody Receives U.S.

Antibody 52

Antibody 52

BioTech 365

NOVEMBER 18, 2020

John Montalbano Joins AbCellera’s Board of Directors John Montalbano Joins AbCellera’s Board of Directors VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat … Continue reading →

Antibody 52

Antibody Development 52

Pharmaceutical Technology

FEBRUARY 15, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. In terms of application diversity, Vivoryon Therapeutics is the top company, followed by MannKind, and Onxeo SA.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

Pharmaceutical Technology

MARCH 9, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Sanofi and F. Hoffmann-La Roche are the other key patent filers in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Drug Discovery World

OCTOBER 26, 2023

The company’s lead therapeutic cancer vaccine candidate is currently being evaluated in Phase III study for melanoma. Dr Raffi Tonikian, Director of Translational Biomarkers at AbCellera. The company works with some of most influential companies in the drug discovery space, pushing antibody discovery programmes forward.

Research 52

Research Antibody Vaccination Vaccine 52

pharmaphorum

AUGUST 7, 2020

Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales. The perception of pharma and medical companies has surged upward since the start of the COVID-19 pandemic, but they still lie mostly outside the top-rated firms in the FutureBrand Index.

Sales 103

Sales Antibody Vaccination Vaccine 103

pharmaphorum

SEPTEMBER 17, 2020

The company hopes to confirm this finding in ongoing studies, and added that across all treatment groups, no patients progressed to mechanical ventilation or died. The antibody emerged from a collaboration between Lilly and AbCellera to create antibody therapies to counter the pandemic.

Antibody 122

Antibody RNA Trials Clinical Trials 122

The Pharma Data

DECEMBER 8, 2020

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies. . Investments will be made in about 15 therapeutics companies, with a third created by Forbion through its “Build” opportunities. The rest will be invested in “highly impactful existing companies.” Nuance Pharma .

RNA 52

RNA Antibody Life Science Protein 52

pharmaphorum

SEPTEMBER 18, 2020

With vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the capacity to make them at scale, as new deals for BioNTech and Eli Lilly this week indicate. The antibody emerged from a collaboration between Lilly and AbCellera to create antibody therapies to counter the pandemic.

Manufacturing 52

Manufacturing Antibody Vaccination Vaccine 52

The Pharma Data

AUGUST 7, 2020

CluePoints , a software company specializing in the life sciences sector, has issued clinical studies affected by the Covid-19 pandemic with risk management support packages to ensure ongoing and new clinical trials can perform risk planning and mitigation activities during the global health crisis. “Our

Clinical Trials 52

Clinical Trials Clinical Trials Gene Trials 52

Drug Discovery World

FEBRUARY 16, 2024

Antibody discovery The final presentation was given by Dr Raffi Tonikian, Director of Translational Biomarkers at AbCellera. Moreover, he shared a use case of a Phase I clinical trial, including results, data, and the challenges involved.

Research 52

Research In-Vitro Drugs Vaccination 52

pharmaphorum

DECEMBER 8, 2020

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The company says in its IPO prospectus that it plans to list its shares on the Nasdaq Global Market under the ABCL ticker.

Drugs 100

Drugs Antibody FDA Approval Pharma Companies 100

The Pharma Data

FEBRUARY 12, 2022

Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today. “As a global pharmaceutical company, Lilly has worked hard to fight this pandemic. and Company?.

Antibody 40

Antibody Trials Clinical Trials Clinical Trials 40

The Pharma Data

APRIL 14, 2021

Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

Antibody 52

Antibody Protein Scientist Development 52

The Pharma Data

APRIL 16, 2021

– Lilly, in collaboration with Amgen, expects to manufacture sufficient supply for complete global transition by June Eli Lilly and Company (NYSE: LLY) has requested the U.S. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

Antibody 52

Antibody Development Medicine Protein 52

The Pharma Data

AUGUST 3, 2021

. – Year-to-date revenue grew 11 percent – excluding revenue from COVID-19 antibodies – with strong sequential growth from first quarter to second quarter 2021, suggesting continued recovery from the COVID-19 pandemic in line with company expectations. – Second-quarter 2021 earnings per share (EPS) decreased to $1.53

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. About Eli Lilly and Company? Source link.

Antibody 52

Antibody Medicine FDA Approval Licensing 52

pharmaphorum

AUGUST 3, 2020

The US drugmaker is testing the antibody – called LY-CoV555 and developed in collaboration with Canadian biotech AbCellera – in a phase 3 trial to see if it can prevent the spread of the coronavirus among residents and staff in US nursing homes.

Nurses 59

Nurses Antibody Trials Clinical Trials 59

Delveinsight

DECEMBER 8, 2020

AbCellera Biologics readies to raise up to USD 391 million in IPO. Canadian antibody-drug discovery platform AbCellera Biologics is setting the groundwork for a massive Initial public offering worth USD 391 million. The company is offering 23 million shares priced between USD 14 and USD 17 each.

Licensing 52

Licensing Licensing Gene Therapy Antibody 52

pharmaphorum

NOVEMBER 5, 2021

The UK-registered company will be able to tap into DeepMind’s AI-powered AlphaFold engine that last year became the first to solve the tricky problem of predicting protein folding, but will operate separately. It also wants to forge alliances with pharmaceutical and biotech companies.

Drugs 72

Drugs Protein Genome Genomics 72

pharmaphorum

FEBRUARY 10, 2021

Bamlanivimab and etesevimab should be administered together via a single intravenous infusion as soon as possible after a positive COVID-19 test and within 10 days of symptom onset, according to a company statement. Results from an ongoing phase 2 study have informed the dosing regime approved by the FDA, the company added.

Antibody 81

Antibody Allergies Nurses Doctors 81

pharmaphorum

NOVEMBER 6, 2022

As a result, 2022 saw a breakthrough when the first ever computationally designed antibody created by Israel-based Biolojic design entered clinical trial , further fuelling the interest of biopharma companies. Although the space is in a nascent stage, several AI companies have made meaningful progress over the last few years.

Antibody 112

Antibody Drugs Protein Life Science 112

The Pharma Data

OCTOBER 28, 2020

28, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. About Eli Lilly and Company? SOURCE Eli Lilly and Company.

Antibody 40

Antibody Medicine Manufacturing Scientist 40

XTalks

JANUARY 29, 2021

Bamlanivimab alone is authorized for emergency use as a treatment for high-risk patients with mild to moderate COVID-19 in the US and widely available for use,” said Daniel Skovronsky, MD, PhD, Lilly’s chief scientific officer and president of Lilly Research Laboratories, in a news release from the company.

Antibody 96

Antibody Clinical Trials Clinical Trials Trials 96

XTalks

MARCH 15, 2021

The antibody was developed in conjunction with Vancouver-based AbCellera. Bamlanivimab first received FDA authorization in November of last year as a standalone treatment for high-risk COVID-19 patients as a single dose 700 mg infusion.

Antibody 92

Antibody Trials Protein Regulation 92

The Pharma Data

JANUARY 26, 2021

Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. About Eli Lilly and Company? SOURCE Eli Lilly and Company. INDIANAPOLIS, Jan. Across 1,035 patients, there were 11 events (2.1 percent) in patients taking therapy and 36 events (7.0

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 26, 2021

Eli Lilly’s bamlanivimab, a neutralizing antibody initially developed by AbCellera, was approved for emergency use authorization in November by the U.S. That ability indicates that the epitope is highly conserved, which may make it more difficult for escape mutants to develop, the companies said.

Antibody 52

Antibody Genotype Trials Nurses 52

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. About Eli Lilly and Company? SOURCE Eli Lilly and Company. INDIANAPOLIS, Nov. 9, 2020 /PRNewswire/ — The U.S.

Antibody 52

Antibody Medicine Manufacturing Trials 52

The Pharma Data

NOVEMBER 9, 2020

Warning Letters: The FDA, along with the FTC issued warning letters to the following companies for selling fraudulent COVID-19 products. EUROIMMUN , a PerkinElmer company, announced the launch of its anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) antibody test. Diagnostics. Organizational Actions/Announcements .

Antibody 52

Antibody Vaccination Vaccine Research 52

The Pharma Data

DECEMBER 20, 2020

Many companies appear to be getting their clinical trial news updated ahead of the holidays. The trial will evaluate one or two drugs on COVID-19, currently Eli Lilly’s LY3819253 (also LY-COV555, an antibody from their collaboration with AbCellera). The DSMB gave the company the go-ahead to continue the trial without changes.

Trials 52

Trials Gene Therapy Vaccination Vaccine 52

Drug Discovery World

NOVEMBER 9, 2023

Thereafter, presentations include: Nathan Frey, PhD, Machine Learning Scientist, Prescient Design, a Genentech Company, on: ‘Lab-in-the-;oop, an ML-driven platform for automated molecular discovery and design’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MARCH 5, 2021

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab.

Antibody 40

Antibody Medicine Regulation Trials 40

The Pharma Data

MARCH 11, 2021

Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.

Trials 40

Trials Antibody Medicine Protein 40

The Pharma Data

NOVEMBER 22, 2020

In October, the company released Phase II/III data that showed treatment with REGN-COV2 significantly reduced viral load and need for additional medical visits in outpatients with COVID-19. Following the data, the company submitted its antibody treatment for EUA. Through Operation Warp Speed, the U.S. Featured Jobs on BioSpace.

Antibody 52

Antibody Immune Response Protein Manufacturing 52

The Pharma Data

MAY 4, 2021

Gilead sues Russia over a compulsory license issued to a company making remdesivir ( STAT ). Lilly’s Covid-19 partner AbCellera is taking a new antibody into the clinic in the hopes it can tackle all variants ( Endpoints ). . Denmark drops J&J Covid vaccine over blood clot concerns ( FT ).

Vaccination 52

Vaccination Vaccine FDA Approval Regulation 52

Pharmaceutical Technology

JUNE 15, 2023

Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates. In March 2023, Confo Therapeutics and Eli Lilly and Company entered a global licence agreement for the former’s clinical-stage peripheral pain candidate, CFTX-1554.

Antibody 130

Antibody Sales Protein Development 130

XTalks

NOVEMBER 11, 2020

Related: Eli Lilly and AbCellera Begin Phase I Trials for a COVID-19 Antibody Treatment. Eli Lilly had partnered with AbCellera to design and test the antibody, which was initially isolated from the blood of a recovered COVID-19 patient. Ricks, Lilly’s chairman and CEO, in a news release from the company.

Antibody 59

Antibody Drugs Trials FDA Approval 59